Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
265.4 CHF | +2.39% | +4.98% | +1.53% |
06-07 | Roche: efficacy of Evrysdi in spinal muscular atrophy | CF |
06-07 | Roche's Five-year Data Confirms Efficacy, Safety of Evrysdi Drug for Spinal Muscular Atrophy in Children | MT |
Sales 2024 * | 60.39B 67.33B 5,299B | Sales 2025 * | 63.83B 71.17B 5,601B | Capitalization | 196B 219B 17,215B |
---|---|---|---|---|---|
Net income 2024 * | 13.27B 14.79B 1,164B | Net income 2025 * | 14.76B 16.46B 1,295B | EV / Sales 2024 * | 3.48 x |
Net Debt 2024 * | 13.77B 15.35B 1,208B | Net Debt 2025 * | 7.88B 8.79B 691B | EV / Sales 2025 * | 3.2 x |
P/E ratio 2024 * |
14.3
x | P/E ratio 2025 * |
12.9
x | Employees | 103,605 |
Yield 2024 * |
4.04% | Yield 2025 * |
4.15% | Free-Float | 88.91% |
Latest transcript on Roche Holding AG
1 day | +2.39% | ||
1 week | +4.98% | ||
Current month | +4.98% | ||
1 month | +10.93% | ||
3 months | +5.07% | ||
6 months | -0.11% | ||
Current year | +1.53% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 49 | 31/12/02 | |
Severin Schwan
CHM | Chairman | 57 | 31/12/07 |
Alan Hippe
DFI | Director of Finance/CFO | 57 | 31/03/11 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bernard Poussot
BRD | Director/Board Member | 72 | 02/03/15 |
Director/Board Member | 59 | - | |
Director/Board Member | 66 | 31/12/95 |
Date | Price | Change | Volume |
---|---|---|---|
07/06/24 | 268.8 | +1.28% | 2,487 |
06/06/24 | 265.4 | +0.99% | 2,950 |
05/06/24 | 262.8 | +1.23% | 2,902 |
04/06/24 | 259.6 | +1.41% | 1,830 |
03/06/24 | 256 | +1.27% | 1,246 |
Delayed Quote London S.E., June 06, 2024 at 04:43 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+45.82% | 754B | |
+40.95% | 630B | |
-6.16% | 352B | |
+19.86% | 331B | |
+9.32% | 298B | |
+18.45% | 250B | |
+11.88% | 217B | |
+5.90% | 164B | |
-0.73% | 163B |
- Stock Market
- Equities
- ROG Stock
- 0QQ6 Stock